Cargando…

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C

BACKGROUND: There is no information on the clinical effectiveness of Maraviroc (MVC) amongst People Living with HIV (PLHIV) in India infected with HIV-1 Subtype C viruses. METHODS: We conducted a retrospective chart review of adult PLHIV on MVC based Antiretroviral (ARV) regimens for at least 6 mont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pujari, Sanjay, Gaikwad, Sunil, Bele, Vivek, Joshi, Kedar, Dabhade, Digamber
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748454/ https://www.ncbi.nlm.nih.gov/pubmed/29473485 http://dx.doi.org/10.1177/2325958218759211

Ejemplares similares

Long‐coronavirus disease among people living with HIV in western India: An observational study
por: Pujari, Sanjay, et al.
Publicado: (2021)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom
por: Pujari, Sanjay N, et al.
Publicado: (2014)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients
por: Piconi, Stefania, et al.
Publicado: (2016)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects
por: Ghannad, M., et al.
Publicado: (2019)

Multivariate Chemometric Comparison of Forced Degradation and Electrochemical Oxidation LC–MS Profiles of Maraviroc
por: Wroński, Michał, et al.
Publicado: (2023)

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
por: Borm, Katharina, et al.
Publicado: (2016)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8222mghfqgqcpbl41o1usi2lri